R&D rebate strengthens cash position
Filed with ASX · · 2 pages · English
Sydney, 27 February 2026: Innovative biotech company Noxopharm Limited (ASX:NOX) has received a $2,806,583.03 rebate under the Australian Government’s Research and Development Tax Incentive scheme for expenditure during FY 2025. Noxopharm CEO Dr Gisela Mautner said: “We have made substantial progress over the past 12 months, and this R&D rebate helps strengthen our cash position as we continue to
Earlier from Noxopharm
- At-the-Market (ATM) agreement with Acuity Capital
- Sofra breakthrough science publish in major medical journal
- December 2025 Quarterly Activities Report and Appendix 4C
- HERACLES clinical trial successfully completed
- HERACLES clinical trial Update 5
Later from Noxopharm
- Appendix 4D and FY2026 Half Year Financial Report
- Resignation of Chief Executive Officer
- Noxopharm appoints Dr Olivier Laczka as new CEO
- Positive SOF-SKN dosing data shows prolonged skin retention
- March 2026 Quarterly Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm